Month: September 2026

Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment intensification

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The conference will take place September 26–30 in Boston.

The presentations include analyses from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. Together, they examine Decipher’s prognostic value in assessing disease risk and predictive value in identifying which patients may benefit from treatment intensification, including adding androgen-deprivation therapy (ADT) to radiation.

“The breadth of research being presented at ASTRO underscores the growing role of genomic information in helping clinicians navigate complex prostate cancer treatment decisions,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “These presentations demonstrate how elucidating the molecular components of tumor biology may help personalize treatment decisions for patients across different stages of disease.”

The following Decipher-focused studies will be presented at ASTRO 2026:

Oral Presentations

• Title: Evaluation of PAM50 Molecular Subtypes in Post-Prostatectomy Salvage Radiotherapy: An NRG Oncology-RTOG 0534 Analysis
  Presenter: Shuang Zhao, M.D., M.S.E.
  Abstract: 6
  Date/Time: Sunday, September 27, 1:30–1:40 p.m. ET
  Location: Grand Ballroom
• Title: The Role of Docetaxel In Addition to Salvage Radiation and Androgen Deprivation In Men with High Risk Prostate Cancer Post-Prostatectomy: Results of NRG GU002
  Presenter: Mark Hurwitz, M.D., FASTRO
  Abstract: 250
  Date/Time: Tuesday, September 29, 12:40–12:50 p.m. ET
  Location: Room 210
• Title: Genomic Stratification of Benefit From Short-Term Androgen Deprivation With Dose-Escalated Radiotherapy in Intermediate-Risk Prostate Cancer: An Ancillary Study of RTOG/NRG 0815
  Presenter: Angela Jia, M.D., Ph.D.
  Abstract: 312
  Date/Time: Tuesday, September 29, 3:55– 4:05 p.m. ET
  Location: Room 210
• Title: Multi-institutional Transcriptomic Characterization of Radiorecurrent Prostate Cancer and Prognostic Biomarkers After Salvage Re-irradiation in the F-SHARP Clinical Trial
  Presenter: Abhishek Solanki, M.D., M.S.
  Abstract: 314
  Date/Time: Tuesday, September 29, 4:15–4:25 p.m. ET
  Location: Room 210
• Title: Long-Term Transcriptomic Analysis of NRG/RTOG 9601: A Phase 3 Study of Salvage Radiotherapy for Prostate Cancer with or without Anti-Androgen Therapy
  Presenter: Krishnan Patel, M.D.
  Abstract: 315
  Date/Time: Tuesday, September 29, 4:25–4:35 p.m. ET
  Location: Room 210

Quick-Pitch Presentation

• Title: Real-World Evidence across Prostate RT Modalities: Utilization Shifts, Toxicity and BCR in Genomic Classifier Scored Patients
  Presenter: Thomas Kole, M.D., Ph.D.
  Abstract: 1166
  Date/Time: Tuesday, September 29, 5:35–5:40 p.m. ET
  Location: Room 205

Poster Presentations

• Title: Preoperative Biopsy Decipher Prostate Genomic Classifier Predicts Earlier Secondary Radiotherapy After Radical Prostatectomy in National Real-World Data
  Presenter: Thomas Kole, M.D., Ph.D.
  Abstract: 3297
  Date/Time: Sunday, September 27, 2:15–3:30 p.m. ET
  Location: Poster Hall, Exhibit Hall A
• Title: Association of 22-Gene Genomic Classifier with ADT Use with Secondary Radiotherapy: A National Real-World Analysis
  Presenter: Andrew Barsky, M.D.
  Abstract: 3226
  Date/Time: Tuesday, September 29, 2:15–3:30 p.m. ET
  Location: Poster Hall, Exhibit Hall A

Additional information is available through the ASTRO 2026 Annual Meeting program.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements regarding the potential role of genomic information in helping identify which patients may benefit from treatment intensification and helping clinicians navigate prostate cancer treatment decisions and personalize treatment decisions for patients across different stages of disease. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “expect,” “may,” “potential,” “will,” and similar expressions. Actual results may differ materially from those expressed or implied by these statements due to risks and uncertainties described under the caption “Risk Factors” in Veracyte’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this release, and Veracyte disclaims any obligation to update them except as required by law.

Veracyte, the Veracyte logo and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the United States and selected countries.

Investors: 
Kelly Gura  
investors@veracyte.com

Media: 
Molly Cornbleet 
media@veracyte.com 
+1 650-351-8780

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) — Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund’s monthly distributions for October, November and December 2026.

Q4 2026 Distribution Schedule

Month	Record Date	Ex-Dividend Date	Payable Date	Amount per Share
October 2026	October 9, 2026	October 9, 2026	October 23, 2026	$0.1180
November 2026	November 12, 2026	November 12, 2026	November 27, 2026	$0.1180
December 2026	December 10, 2026	December 10, 2026	December 24, 2026	$0.1180

Shares purchased on or after the applicable ex-distribution dates will not receive the distributions discussed above. Distributions may include net investment income, capital gains and/or return of capital. Any portion of the Fund’s distributions that is a return of capital does not necessarily reflect the Fund’s investment performance and should not be confused with “yield” or “income.” The Fund’s Section 19a-1 Notice, if applicable, contains additional distribution composition information and may be obtained by visiting https://privatewealth.brookfield.com/fund/brookfield-real-assets-income-fund-inc. The tax status of distributions will be determined at the end of the taxable year. Based on current estimates, it is anticipated that a portion of the distributions paid in calendar year 2026 will be treated for U.S. federal income tax purposes as a return of capital. The final determination of the tax status of those 2026 distributions will be made in early 2027 and provided to stockholders on Form 1099-DIV. Please contact your financial advisor with any questions.

Brookfield Real Assets Income Fund Inc. is managed by Brookfield Public Securities Group LLC. The Fund uses its website as a channel of distribution of material information about the Fund. Financial and other material information regarding the Fund is routinely posted on and accessible at https://privatewealth.brookfield.com/fund/brookfield-real-assets-income-fund-inc

Media enquiries
Rachel Wood:  E rachel.wood@brookfield.com  |  T (212) 613-3490
Investor Relations:  E privatewealth@brookfield.com  |  T (855) 777-8001

Investing involves risk; principal loss is possible. Past performance is not a guarantee of future results.
Brookfield Real Assets Income Fund Inc. is distributed by Foreside Fund Services, LLC.

SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the Company received a notice (the “Notice”) from the staff of NYSE American LLC (the “NYSE American”) that the Company was not in compliance with the NYSE American’s continued listing standards in Part 10, Section 1003(a)(ii)of the NYSE American Company Guide (the “Company Guide”)requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice also indicates that the Company is not currently eligible for any exemption in Section 1003(a) of the Company Guide (including the exemption provided for companies with total value of market capitalization exceeding $50 million among other things).

In connection with its non-compliance with Section 1003(a)(ii), the Company must submit a plan (the “Plan”) to the NYSE American by October 21, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards by March 21, 2028. If the NYSE American determines to accept the Plan, the Company will be notified in writing and will be subject to periodic reviews, including quarterly monitoring for compliance with the Plan. If the Company does not submit a plan or if the Plan is not accepted, NYSE American will commence delisting proceedings. Furthermore, if the Plan is accepted but the Company is not in compliance with the continued listing standards by March 21, 2028, or if the Company does not make progress consistent with the Plan, the NYSE American will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.

The Notice has no immediate effect on the listing or trading of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and the Common Stock will continue to trade on the NYSE American under the symbol “CLDI”, but will have an added designation of “.BC” to indicate the status of the common stock are “below compliance.” The Notice does not affect the Company’s ongoing business operations or its reporting requirements with the U.S. Securities and Exchange Commission.

The Company’s management is reviewing its options to address the deficiencies and expects to submit a compliance plan on or before the deadline set by the NYSE American.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.

CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.

Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.

Forward-Looking Statements

This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding Calidi’s intention to submit a plan to regain compliance with NYSE American’s continued listing standards, NYSE American’s acceptance of any such plan, and Calidi’s ability to regain compliance by March 21, 2028. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that NYSE American does not accept Calidi’s compliance plan; the risk that Calidi is unable to regain compliance with NYSE American’s continued listing standards by March 21, 2028, or to make progress consistent with its plan during the plan period; the risk that NYSE American commences delisting proceedings, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials or to increase its stockholders’ equity; and, risks related to changes in applicable laws or regulations; manufacturing and supply chain matters; the availability of capital and other resources; and changes in business, market, economic or competitive conditions. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 27, 2026, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Investors Contact:
IR@calidibio.com

Media Contact:
PR@calidibio.com

EDMONTON, Alberta, Sept. 25, 2026 (GLOBE NEWSWIRE) — Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today announces the change of its Chief Executive Officer (CEO). Effective November 23, 2026, Dr. Madi Madiyalakan will be retiring from his position as Quest’s CEO. Dr. Madiyalakan has been the CEO of Quest since August 2006. Mr. Jeffrey Shon, a director of Quest, will be taking over the role of CEO. Mr. Shon has considerable experience in the areas of legal, regulatory and corporate affairs, including venture capital funding focused on emerging technologies.

J. Mark Lievonen, Chairman of Quest’s Board, stated, “We thank Dr. Madiyalakan for his tireless efforts, hard work and unwavering loyalty to Quest over the past 20 years, and we wish him all the best in his future endeavors. We welcome Mr. Shon, as CEO of Quest following Dr. Madiyalakan’s retirement, and wish him success in his efforts to run the Company and create shareholder value.”

Quest also announces that it will hold its annual and general shareholder meeting (AGM) on Monday, November 23, 2026, at 3:00 pm in the Company’s corporate offices in Edmonton. Dr. Madiyalakan will not be standing for re-election as a director at the AGM but will continue to consult to Quest as required to ensure continuity of its business operations.

About Quest PharmaTech Inc.

Quest PharmaTech Inc is a publicly traded, Canadian based biopharmaceutical company (QPT: TSX-V) developing products to improve the quality of life. The Company has a 26.6% ownership interest in a Korean company called OQPBIOM Inc., a private company that owns the immunotherapy assets and is developing immunotherapeutic products for the treatment of cancer. Quest also has a 23% ownership interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the Greater China territory. Quest is also developing proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer which is currently in late preclinical stage. To learn more, visit www.questpharmatech.com. 

Forward Looking Statements  

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen. The forward-looking information contained herein is made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation, the risk factors that can be found in the Company’s securities law filings which have been filed under the Company’s SEDAR+ profile at www.sedarplus.ca. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

For further information:
Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc.
Tel: (780) 448-1400,
E-mail: madi@questpharmatech.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

San Francisco, CA, Sept. 25, 2026 (GLOBE NEWSWIRE) — Future Money Acquisition Corporation (Nasdaq: FMAC) (the “Company”) announced today that on September 22, 2026, the Company received a deficiency letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026 (the “Form 10-Q”), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission.

The Notice states that the Company has 60 calendar days from the date of the Notice, or until November 23, 2026, to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) (the “Plan”). If Nasdaq accepts the Plan, Nasdaq may grant the Company an exception of up to 180 calendar days from the Form 10-Q filing due date, or until March 22, 2027, to regain compliance. If Nasdaq does not accept the Plan, the Company will have the opportunity to appeal that determination to a Nasdaq Hearings Panel.

The Company is working diligently to complete and file the Form 10-Q as soon as practicable. The Company intends to take all necessary steps to regain compliance with the Nasdaq Listing Rules. However, there can be no assurance that the Company will take the steps necessary to regain compliance within the required period, that the Plan will be accepted by Nasdaq, that the Company will be granted an exception, or that the Company will be able to meet the conditions of any exception or the continued listing requirements during any compliance period that may be granted.

Future Money Acquisition Corporation

The Company is a blank check company newly incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including those with respect to the anticipated timing for filing the Form 10-Q and the Company’s ability to regain compliance with Nasdaq’s listing rules, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements, including risks related to the completion of the Company’s interim financial statements and related interim review, the Company’s ability to file the Form 10-Q within the anticipated timeframe, the Company’s ability to regain and maintain compliance with Nasdaq’s continued listing requirements, and those set forth in the Risk Factors section of the Company’s registration statement and final prospectus for the Company’s initial public offering filed with the SEC. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law. Investors should not place undue reliance on the Company’s forward-looking statements.

Contact Information:

Future Money Acquisition Corporation
Siyu Li
steven.li@fumoac.com 

BOSTON, MA, Sept. 25, 2026 (GLOBE NEWSWIRE) — Netcapital Inc. (Nasdaq: NCPL) (the “Company”) today announced that on September 21, 2026, it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026, and remains delinquent in filing its Annual Report on Form 10-K for the fiscal year ended April 30, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). That rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.

As previously announced on August 27, 2026, the Company received an earlier notice from Nasdaq on August 24, 2026 regarding the delinquent Form 10-K. Under that notice, the Company has until October 23, 2026 to submit a plan to regain compliance covering both delinquent reports. If Nasdaq accepts the plan, it may grant the Company an exception of up to 180 calendar days from the original due date of the Form 10-K, or until February 9, 2027, to regain compliance. If Nasdaq does not accept the plan, the Company may appeal to a Nasdaq Hearings Panel.

The notice has no immediate effect on the listing or trading of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol “NCPL.”

The Company intends to submit its compliance plan within the required timeframe and to file the Form 10-K and Form 10-Q as soon as practicable. There can be no assurance that Nasdaq will accept the plan or that the Company will regain compliance within any exception period granted.

About Netcapital Inc.

Netcapital Inc. is a fintech company with a scalable technology platform that allows private companies to raise capital online and provides private equity investment opportunities to investors. The Company’s consulting group, Netcapital Advisors, provides marketing and strategic advice and takes equity positions in select companies. The Company’s funding portal, Netcapital Funding Portal, Inc., is registered with the U.S. Securities and Exchange Commission and is a member of the Financial Industry Regulatory Authority. The Company’s broker-dealer, Netcapital Securities Inc., is also registered with the SEC and is a member of FINRA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plan to regain compliance with Nasdaq’s listing rules and the timing of its periodic filings. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the Company’s ability to complete the audit and review of its financial statements, the availability of financing, Nasdaq’s acceptance of the Company’s plan, and other risks described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements, except as required by law.

Contact:
800-460-0815 
ir@netcapital.com